Post marketing study of sofosbuvir and ledipasvir for genotype 1 hepatitis C virus infection

Post marketing study of sofosbuvir and ledipasvir for genotype 1 hepatitis C virus infection - Sofosbuvir and ledipasvir for genotype 1 HCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023271

Enrollment

200

Registered

2016-07-21

Start date

2015-09-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with genotype 1 HCV infection

Exclusion criteria

Exclusion criteria: 1) pregnant woman 2) decompensated cirrhosis 3) severe renal dysfunction (<eGFR30)

Design outcomes

Primary

Measure	Time frame
Sustained virological response at 12 weekes after the end of therapy	—

Countries

Japan

Contacts

Public ContactHideyuki Tamai

Wakayama Medical University Second department of internal medicine

tamahide@wakayama-med.ac.jp073-447-2300

Outcome results